Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness

Fig. 4

The incremental Net Monetary Benefit (iNMB). Caption: Shows the incremental Net Monetary Benefit (iNMB) for both the Dutch informal WTP threshold of €80,000 and for the WTP threshold that is mainly used in the United Kingdom of £30,000 (€34,821). A mean NMB ≥ €0 indicates that TIL therapy is cost-effective compared to ipilimumab given the chosen threshold

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us